Milestone Pharmaceuticals AI Stock Analysis
Want to see MIST full AI Analyst Report?
Milestone Pharmaceuticals (MIST) AI Stock Analysis
Milestone Pharmaceuticals
(NASDAQ:MIST)
The score is held down primarily by weak financial fundamentals (large operating losses, heavy cash burn, and negative equity) and a pronounced bearish technical setup (below all major moving averages with negative MACD). The latest earnings call provides a partial offset through improved prescription momentum and guidance for significant cost reductions that extend runway, but valuation is not supportive due to ongoing losses and no dividend yield.
Milestone Pharmaceuticals (MIST) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $46.20M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.53M
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 2.58
- Revenue Growth
- ―
- EPS Growth
- 12.79%
- Country
- US
- Employees
- 38
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Milestone Pharmaceuticals Business Overview & Revenue Model
Company Description
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently...
Milestone Pharmaceuticals Earnings Call Summary
The call reflected solid commercial and clinical progress, including 50% sequential prescription growth, expanding prescriber breadth, broader commercial coverage, improved refill trends, and an extended cash runway through the planned AFib-RVR phase III readout. However, these positives were balanced by substantial operating losses, elevated launch-related SG&A, workforce reductions, incomplete payer coverage, adoption friction, and limited near-term Medicare contribution. Overall, management was cautiously optimistic while acknowledging that prescription growth and commercial execution still need to improve.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects cost-efficiency measures to reduce operating expenses by approximately 30%, with the entire process completed by the first quarter of 2027 and approximately $2 million in one-time charges; extending the operating cash runway into late 2028, more than one year beyond prior guidance, and through the anticipated phase III readout of ReVeRA-301 in the second half of 2028. Management said it does not guide to numbers for prescriptions but expects shifting up in Q4, Q1 shifting down a little as out-of-pockets and insurance plans reset, potentially starting to again inflect up in Q2, and ramping up through the second half of 2027. ReVeRA-301 is sized to about 150 events over a period of about two years, with enrollment somewhere in the range of 500 to maybe even 700 patients; for symptomatic benefit, management is looking for people to reach the six and seven category at a rate of about 45% for etripamil versus 20% for placebo, with powering greater than 90% using a two-sided alpha to get to a 0.05.
Milestone Pharmaceuticals Financial Statement Overview
Summary
Despite a sharp TTM revenue rebound (~$5.3M) with very high gross margin (~92%), the company remains deeply unprofitable (EBIT about -$91.7M) with substantial ongoing cash burn (operating cash flow about -$76.1M TTM). Balance sheet risk is elevated with negative stockholders’ equity (-$6.2M) and higher debt (~$60.9M), increasing financing/dilution risk.
Income Statement
22NegativeBalance Sheet
18Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.31M | 1.55M | 0 | 1.00M | 5.00M | 15.00M |
| Gross Profit | 4.88M | 1.43M | 0 | 1.00M | 5.00M | 15.00M |
| EBITDA | -85.76M | -59.45M | -37.83M | -57.04M | -58.30M | -42.49M |
| Net Income | -97.89M | -63.06M | -41.52M | -59.69M | -58.39M | -42.85M |
Balance Sheet | ||||||
| Total Assets | 162.69M | 113.56M | 75.50M | 75.23M | 74.48M | 119.85M |
| Cash, Cash Equivalents and Short-Term Investments | 145.35M | 105.96M | 69.69M | 66.00M | 64.58M | 114.14M |
| Total Debt | 60.94M | 58.38M | 54.80M | 51.77M | 2.49M | 698.00K |
| Total Liabilities | 168.91M | 71.79M | 62.35M | 58.45M | 8.13M | 7.25M |
| Stockholders Equity | -6.22M | 41.77M | 13.15M | 16.77M | 66.35M | 112.60M |
Cash Flow | ||||||
| Free Cash Flow | -76.16M | -49.34M | -28.88M | -46.54M | -52.74M | -33.22M |
| Operating Cash Flow | -76.12M | -49.04M | -28.85M | -46.42M | -52.47M | -33.22M |
| Investing Cash Flow | 34.33M | 11.25M | 8.28M | 4.76M | -57.12M | 70.00M |
| Financing Cash Flow | 138.83M | 85.53M | 32.12M | 47.79M | 3.09M | 5.05M |
Milestone Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MIST, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.63, below the 50-day MA of 0.73, and below the 200-day MA of 1.27, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 29.94 is Positive, neither overbought nor oversold. The STOCH value of 11.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MIST.
Milestone Pharmaceuticals Risk Analysis
Milestone Pharmaceuticals disclosed 72 risk factors in its most recent earnings report. Milestone Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksMilestone Pharmaceuticals Peers Comparison
Overall Rating
ANRO49Neutral
CRBP46Neutral
MIST45Neutral
ELTX39Underperform
AVTX38Underperform
MCRB38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $1.06B | -10.15 | -41.82% | ― | ― | -8.20% | |
| 46Neutral | $50.18M | -0.32 | -100.96% | ― | ― | -10.49% | |
| 45Neutral | $49.71M | -0.49 | -435.92% | ― | ― | 12.79% | |
| 39Underperform | $42.46M | -0.79 | -529.69% | ― | ― | 46.62% | |
| 38Underperform | $390.31M | -2.34 | -34.21% | ― | -69.27% | 66.84% | |
| 38Underperform | $13.56M | -0.25 | -148.34% | ― | 505.41% | -889.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MIST | Milestone Pharmaceuticals | 0.37 | -2.00 | -84.35% | |
| CRBP | Corbus Pharmaceuticals Holdings | 2.06 | -9.38 | -81.99% | |
| MCRB | Seres Therapeutics Inc. | 1.24 | -15.73 | -92.69% | |
| AVTX | Avalo Therapeutics, Inc. | 6.76 | -11.24 | -62.44% | |
| ELTX | Elicio Therapeutics, Inc | 1.45 | -7.17 | -83.18% | |
| ANRO | Alto Neuroscience, Inc. | 25.37 | 12.07 | 90.75% |
Milestone Pharmaceuticals Corporate Events
Milestone Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
NegativeOn October 23, 2026, Milestone Pharmaceuticals Inc. disclosed that it received a notice from Nasdaq stating its common shares had closed below the $1.00 minimum bid price requirement for 30 consecutive business days, putting the company out of compli...
Milestone Wins China Approval for Etripamil Nasal Spray
PositiveOn September 3, 2026, Milestone Pharmaceuticals announced that China’s National Medical Products Administration approved etripamil nasal spray for treating paroxysmal supraventricular tachycardia in adults, marking the first regulatory authorization...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 19, 2026
